SHR-A1811 binds HER2 on tumor cells, is internalized, and releases a camptothecin-derived topoisomerase I inhibitor that causes DNA damage and apoptosis. DNA topoisomerase I is the intracellular enzymatic target of the payload, not the recognition antigen; cells expressing topo I alone are not specifically targeted.